Abstract
There is now good evidence to support the use of HMG-CoA reductase inhibitors in the primary and secondary prevention of coronary heart disease (CHD). It is thought that the maximum benefit of such treatment can only be obtained with life-long treatment. Since these drugs are expensive, their use is now being scrutinised from a cost-effectiveness point of view, as discussed at the 18th Congress of the European Society of Cardiology (ESC) [ Birmingham, UK; August 1996 ]. As a comparison, the cost-effectiveness of tocopherol [vitamin E] in people with proven atherosclerosis was also discussed.
Rights and permissions
About this article
Cite this article
Jack, D.B. Reducing costs by reducing lipid levels in CHD. Inpharma Wkly. 1060, 7–8 (1996). https://doi.org/10.2165/00128413-199610600-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199610600-00013